000403 派林生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,618,147-14.40%2,654,6852,328,7232,405,1881,971,734
减:营业总成本1,204,150-5.90%1,815,7281,639,4961,753,3341,487,436
    其中:营业成本868,646-7.13%1,350,3981,129,8781,151,4431,063,309
               财务费用(27,670)-25.11%(49,170)(57,572)(55,315)(45,777)
               资产减值损失(1,225)--(1,254)--124(103,679)
公允价值变动收益(5,804)-45.21%6,381(18,970)4,92974,208
投资收益16,101-45.22%17,7397,4023,0383,701
    其中:对联营企业和合营企业的投资收益------------
营业利润431,463-32.45%880,313695,188663,429460,427
利润总额406,937-34.32%852,778688,109660,392458,011
减:所得税费用49,440-35.62%107,73676,63672,70266,471
净利润357,497-34.13%745,042611,472587,690391,540
减:非控股权益3161,139.25%(279)(639)559476
股东净利润357,181-34.19%745,321612,111587,131391,064

市场价值指针
每股收益 (元) *0.380-33.33%1.0200.8400.8040.554
每股派息 (元) *----0.5000.2000.0800.056
每股净资产 (元) *8.445-20.96%10.84010.1359.3778.631
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容